Social networks
892 6,569Activities
Technologies
Entity types
Location
Babraham Hall, Babraham, Cambridge CB22 3AT, UK
Babraham
United Kingdom
Employees
Scale: 11-50
Estimated: 56
Engaged corporates
4Added in Motherbase
5 years, 4 months agoCrescendo Biologics - The T cell Enhancing Company
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody.
The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.
Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 30 Nov 2023 | | |
Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 29 Sep 2023 | | |
Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 27 Nov 2020 | | |
IP Group plc Financial Services | IP Group plc Financial Services | Not capitalistic Partnership Not event 24 Sep 2019 6 Dec 2023 | | |